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Drug Receptor Identification from Multiple Tissues
Using Cellular-Derived mRNA Display Libraries
matography [3–9] and affinity labeling [10–14] have been
employed to facilitate the purification and identification
of drug binding proteins. However, these approaches
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128 Spring Street often fail after laborious efforts to isolate and micro-
sequence proteins that are unstable, are expressed atLexington, Massachusetts 02421
levels below the sensitivity of detection, or are inade-
quately pure for unambiguous characterization. To cir-
cumvent these problems, several expression-cloningSummary
methods have been developed to detect natural prod-
uct-protein interactions [15]. Yeast-three hybrid [16],The use of display technologies to identify small mole-
functional expression cloning in tissue culture cells [17],cule receptors from proteome libraries would provide
drug-Western [18], and phage-display cloning [19] havea significant advantage in drug discovery. We have
all allowed the encoded proteins from cDNA libraries toused mRNA display to select, based on affinity, pro-
be probed for ligand binding activity. However, each ofteins that bind to a drug of interest. A library of mRNA-
these techniques has inherent limitations arising fromprotein fusion molecules was constructed from human
the constraints of working within an in vivo system. Aliver, kidney, and bone marrow transcripts and se-
methodology that combines the versatility of in vitrolected using an immobilized FK506-biotin conjugate.
cDNA manipulation with drug affinity chromatographyThree rounds of selection produced full-length
would provide significant benefits. mRNA display [20,FKBP12 (FK506 binding protein 12 kDa) as the domi-
21], where libraries of proteins are covalently linked tonant clone. An analogous method was also used to
their encoding mRNA, provides just such a system andmap the minimal drug binding domain within FKBP12.
has been used to select for small molecule binding pro-Using this approach, it is anticipated that mRNA dis-
teins from a random-sequence library [22]. In addition,play could eventually play a key role in the discovery
mRNA display libraries have been constructed from hu-and characterization of new drug receptor interac-
man tissues that have allowed the discovery of noveltions.
protein-protein [23] and enzyme-substrate [24] interac-
tions. This approach has now been demonstrated to be
Introduction a new tool for the identification of drug receptors using
the FK506-FKBP (FK506 binding protein) interaction as
The identification of bioactive compounds causing en- a model drug-receptor complex [7]. Here, we describe
zyme inhibition and perturbation of receptor or channel the successful selection of full-length FKBP12, a ubiqui-
function has predominated as the basis for medicinal tous receptor of FK506, from a mixture of human
discovery. The majority of these drugs elicit their phar- kidney-, liver-, and bone marrow-derived mRNA display
macological action through binding to known protein libraries using an FK506-biotin conjugate. In addition,
targets. Although well-characterized biological targets the versatility of mRNA display in defining the FK506
continue to provide a strong foundation for therapeutic binding domain within FKBP12 is demonstrated through
intervention, a shift in paradigm has emerged wherein construction of a random-primed cDNA library from an
genomic and proteomic technologies are being utilized FKBP12-containing template, in vitro selection against
to identify new protein targets for drug discovery [1, 2]. a FK506 matrix, and evaluation of the selected proteins
This approach, often referred to as “gene-to-screen,” in drug affinity binding assays.
draws upon the wealth of human and pathogen genome
sequence information now available to identify can-
didate genes for chemical screening. Unfortunately, Results and Discussion
genomic technologies are unable to provide definitive
confirmation of a candidate’s “drugability” before down- The general strategy outlined in Figure 1 was employed
stream affinity-based screens are performed. An alter- for the selection of proteins that bind to a drug or small
native approach to drug target identification involves molecule of interest. Starting from a cDNA template,
high-throughput screening of natural product and/or specific primers are used during PCR to introduce fixed
combinatorial libraries for a desired phenotypic re- sequences required for downstream transcription, puro-
sponse in cells or tissues followed by affinity-based mycin linker ligation, and in vitro translation. Following
identification of cellular proteins that bind to promising translation and fusion formation, the resulting mRNA-
lead compounds. This “screen-to-gene” strategy would protein fusion molecules are then purified and reverse
accomplish two main goals: (1) the discovery of candi- transcribed to create a stable cDNA template for later
date ligands capable of exerting their effect within a amplification. Incubation of the cellular mRNA display
biological milieu, and (2) the identification of target pro- library with an immobilized drug or small molecule is
teins that explicate mechanism of action or toxicity. Tra- performed with subsequent washing to remove un-
ditionally, biochemical techniques such as affinity chro- bound constructs. After elution of bound species and
amplification by PCR, an enriched drug binding library
is generated for further selection. This approach is ame-1Correspondence: mmcpherson@phylos.com
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Figure 1. In Vitro Selection Using mRNA Display
(1) PCR-amplified cDNA is generated using primers that introduce the engineered sequences necessary for transcription, ligation of the
corresponding mRNA, in vitro translation of the mRNA-puromycin linker conjugate, and epitope-based purification of the mRNA-protein fusion.
(2) The engineered PCR product is transcribed to produce mRNA that is then hybridized to a poly-dA-containing linker carrying a 5-psoralen
moiety and a 3 terminus containing the transfer-RNA mimic puromycin (Pu).
(3) UV irradiation produces a covalent crosslink between the mRNA and DNA-puromycin linker [34].
(4) This mRNA-DNA-puromycin conjugate is then used as a template for in vitro translation. The ribosome translates the open reading frame
and pauses at the mRNA-DNA junction.
(5) The absence of a stop codon obviates the action of release factors and allows the conjugate puromycin to enter the A-site of the ribosome.
The peptidyl transferase subunit catalyzes amide bond formation between an amine group on the puromycin and the carboxyl terminus of
the mature protein to give an mRNA-protein fusion.
(6) The fusion is purified after dissociation from the ribosome by virtue of its poly dA linker with oligo-dT cellulose. Reverse transcription of
the fusion creates a cDNA strand that protects the mRNA against degradation and serves as a template for future PCR. Further protein-based
purification of the mRNA display construct also allows the removal of unfused mRNA-DNA-puromycin conjugate.
(7) Libraries of mRNA display molecules, generated from the initial random priming of cellular mRNA, are then incubated with an immobilized
drug or small molecule, and unbound material is removed by washing.
(8) Bound fusion is then eluted either specifically using excess of drug or nonspecifically using KOH. The eluted cDNA then serves as template
to generate a new library enriched for drug binding proteins.
nable to any drug, small molecule, or natural product 2A) was prepared from FK506 1 via esterification of
the less hindered C-32 exocyclic hydroxyl group withthat contains or can be functionalized with an appro-
priate reactive moiety (e.g., hydroxyl, amine, or thiol) succinic anhydride to give the carboxylic acid intermedi-
ate 2. Subsequent treatment with N-hydroxysuccinimidefor direct immobilization with retention of bioactivity. In
examples where little or no SAR information is available (NHS) and dicyclohexylcarbodiimide (DCC) activated
the carboxylic acid for coupling with biotin polyethyleneon the compound, multiple sites of modification may
need to be explored to present the drug in a biologically oxide-long chain-amine (biotin PEO-LC-amine) to yield
the biotinylated FK506 product 3, which was purified byrelevant format. Biotinylation of target compounds with
concomitant avidin-based capture may also be used to preparative thin-layer chromatography. The extended
PEO arm was chosen to impart some hydrophilic char-create an affinity matrix. The latter method of immobili-
zation was chosen to allow more accurate control over acter to the FK506-biotin conjugate and thus assist in
aqueous solubility. In addition, it was anticipated thattethered drug concentrations and to thereby facilitate
downstream affinity ranking of putative selection win- the 23 A˚ spacer would render the FK506 component
more accessible to the mRNA display libraries whileners in binding studies.
The FK506-biotin derivative used in this study (Figure anchored to an avidin-based support.
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Figure 2. Synthesis and Binding Analysis of an FK506-Biotin Derivative to mRNA Display Constructs
(A) Synthesis of an FK506-biotin conjugate (3). (i) Succinic anhydride, DMAP, TEA, rt (ii) NHS, DCC, biotin-PEO-LC-NH2.
(B) Binding of control mRNA display constructs to FK506. FKBP12 and cyclophilin A were prepared as mRNA-protein fusions. Each 35S-labeled
mRNA display construct was incubated with either FK506-biotin immobilized on streptavidin beads () or control beads without drug ().
Percent binding was calculated based on the amount of input material retained on the beads after washing.
The ability of a known drug receptor to bind its natural braries derived from cellular transcripts. Human liver,
kidney, and bone marrow cDNA libraries were synthe-ligand (in an immobilized format) in the context of an
mRNA-protein fusion was assessed as a model system sized individually from commercially available poly(A)
purified mRNA by random priming [23]. The 5 primerto demonstrate the feasibility of selecting a drug recep-
tor(s) from an in vitro mRNA display library. An mRNA included fixed sequence that contained a T7 RNA poly-
merase promoter, a tobacco mosaic virus translationdisplay construct was created from a full-length cDNA
encoding FKBP12 (FK506 binding protein 12 kDa) using initiation site, an 8 nucleotide library-specific sequence
tag, and a start codon directly upstream from the ran-the scheme outlined above. A cyclophilin A (CypA)
mRNA-protein fusion was prepared as a control immu- dom 9 nucleotide priming sequence. The 3 primer in-
cluded sequence coding for the FLAG epitope and anophilin that would not bind to FK506. Each protein
contained a C-terminal sequence encoding the peptide puromycin linker hybridization-photoligation sequence
in addition to the nine random nucleotides. The uniqueDYKDDDDKASA to allow anti-FLAG immunoprecipita-
tion and provide a spacer between the natural terminus sequence tag within the 5-UTR has the advantage of
allowing specific amplification of a particular library fromof the protein and the nucleic acid tail. The 35S-methio-
nine radiolabel incorporated into the protein during in within a mixed pool in addition to identifying cellular
origin when analyzing individual clone sequence uponvitro translation was used to monitor the extent of bind-
ing. Each mRNA-protein fusion was mixed with strepta- completion of a selection with multiple libraries. As ex-
pected, PCR amplification of the individual libraries gavevidin-coated magnetic beads that had been preincu-
bated in the presence or absence of FK506-biotin. After heterogeneous smears of cDNA ranging in size from 200
bp to 1 kb (Figure 3A, Round 0). A mixture of tissue-30 min, the beads were captured and washed with buffer
several times, and the amount of bound fusion was mea- specific mRNA display libraries was prepared from these
PCR products that gave a starting pool of 1.8  1011sured by scintillation counting (Figure 2B). The results
indicated that FKBP12 fusion binding was drug specific, fusion molecules. The absence of in vivo transformation
bottlenecks during library construction coupled with thewith 31.2% of input counts being retained on the FK506
matrix compared with only 0.01% on the control beads. assumption that the human genome contains 30,000
distinct genes [25, 26] suggests that even rare tran-As expected, only 0.3% of the CypA fusion bound to
the FK506 beads (cf. 0.05% control). scripts are well represented in this pool. The mixed li-
braries were incubated with biotin-pretreated streptavi-
din magnetic beads to remove mRNA display constructsSelection of FKBP12 from a Mixed-Tissue mRNA
Display Library that bound nonspecifically to the solid phase. The pre-
cleared library was then mixed with an FK506 affinityThe specificity of the mRNA display-drug interaction
and the low background binding confirmed optimal con- matrix, and washed and bound material was eluted. The
eluate was used as a template for PCR to generate anditions for initiating a selection using mRNA display li-
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Figure 3. PCR Analysis of Human Liver, Kid-
ney, and Bone Marrow mRNA Display Librar-
ies before and after Selection against FK506
(A) PCR product of individual tissue-specific
libraries before selection. Each library dis-
plays cDNA products ranging in size from 200
bp to 1 kb.
(B) PCR profile of mixed-tissue libraries after
one, two, and three rounds of affinity selec-
tion against immobilized FK506. After three
rounds, an intense band was observed mi-
grating at approximately 420 bp, indicating
that the selection had successfully enriched
binding proteins of a consistent size.
enriched cDNA library (Figure 3B, Round 1). A corre- script. Such mutations are not unexpected since the
library was constructed by random priming with a 9spondingly enriched mRNA display pool was then gen-
erated to begin the next round. The progress of the nucleotide region, and any mispairing within these nu-
cleotides will result in a mutation relative to the parentselection was monitored by comparison of the PCR
product between rounds and by the extent of input ra- ORF. Therefore, mutations within the stop codon of a
native transcript are necessary to create productive anddioactivity that bound the immobilized target. After three
rounds, 1.1% of the selected mRNA-protein fusion mole- functional mRNA display constructs of proteins that do
not tolerate truncations at their C terminus. Inclusion ofcules bound the FK506 target, compared with 0.05% in
Round 1 and 0.02% in Round 2. In addition, PCR analysis the first three nucleotides (CAG) of the FKBP12 3-UTR
within the selected message resulted in its translationof the selection showed the progression from an indis-
tinct smear in Rounds 1 and 2 to a strong band migrating as a glutamine codon. Overall, 15 of the selected clones
contained a 2 amino acid (X-Gln) extension immediatelyat 420 bp in Round 3 (Figure 3B, Round 3). This band
was excised, purified, cloned, and sequenced. From a following Glu107 in the parent protein where X is Arg
(73%), Trp (13%), Gly (7%), or Val (7%). Additionally,total of 24 sequences analyzed, 23 belonged to a single
homologous sequence cluster with two identical clones. 25% of these clones isolated contained modifications
at the N terminus of the protein, specifically a deletionA nBLAST sequence search showed the redundant
clone to be FKBP12. Further analysis revealed all 23 of the first two amino acids (Gly-Val) of FKBP12.
Surprisingly, the unique 5-UTR sequence tag identi-sequences aligned with the native ORF of FKBP12, and
19 of those sequences contained the full-length se- fied all 23 sequences as originating from the kidney
library. Although FKBP12 is a ubiquitous cytosolic pro-quence. Specific C-terminal additions were observed in
all of the selected clones when compared to the native tein, there was no precedent to suggest that FKBP12
was present in higher abundance in kidney relative toprotein sequence (Figure 4). These additions arose via
single (80%) or double (20%) nucleotide mutagenesis bone marrow and liver [27]. This bias may have arisen
due to preferential annealing of the kidney-specificwithin the TGA stop codon of the FKBP12 native tran-
Figure 4. Sequence Analysis of Isolated FKBP12 Clones after Selection by mRNA Display
(A) Structure of the FKBP12-FK506 complex [35]. The N and C termini are shown in blue and red, respectively. FK506 is shown in green.
(B) Amino acid sequence of Round 3 clones from a mixed tissue mRNA display library after selection with FK506. Sequence homologous to
FKBP12 is shaded. Out of 24 clones analyzed, 15 contained a 2 amino acid addition (X-Gln, shown in red) relative to the native protein, where
X was either Arg, Trp, Gly, or Val. In addition, four of these clones contained a 2 amino acid truncation at the N terminus (underlined).
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primer during PCR. To determine if the proteins from ates binding to FK506 (Figure 5A). The mRNA template,
comprised of FKBP12 (50%), 5- and 3-UTR (40%), andeither the bone marrow or liver library were enriched
vector (10%) sequence, was used to simulate a drugby selection, library-specific reamplification of Round 3
binding domain within a larger protein, a feature com-was performed. These PCR products were recombined
mon to most immunophilins. The resulting library con-in equimolar amounts prior to transcription and fusion
sisted of a heterogeneous smear of cDNA products thatpreparation. A total of 6.8% of this pool of mRNA-protein
ranged in size from 800 bp to 400 bp and shouldfusion molecules bound the FK506 target matrix (cf.
contain a mixture of extended, full-length, and frag-0.1% preclear beads), and the library-specific amplifica-
mented FKBP12 sequences (Figure 5B, Round 0). Thistion of the recovered cDNA by PCR gave a strong band
starting pool was cloned and sequenced to determinewith an agarose gel mobility similar with that of the
representation. Sequence analysis of 27 random clonesprevious round (data not shown). Cloning and sequenc-
revealed 89% contained a fragment of the FKBP12 cod-ing of these products after purification confirmed the
ing sequence, 11% contained UTR sequence, and onlyselection of full-length FKBP12 from both bone marrow
3% contained the full-length gene. An mRNA displayand liver tissues. The analyzed clones exhibited similar
library was prepared and subjected to three rounds ofdeviations in their predicted protein termini to those
selection against immobilized FK506 using similar con-identified from the kidney-derived sequences.
ditions to the cellular selection. After the third round,The selection and identification of FKBP12 from a
2.2% of mRNA display fusions bound the drug target,cellular-derived mRNA display library using an immobi-
and PCR amplification of eluted cDNA gave a dominantlized FK506 drug target was completed in 3–4 rounds.
band migrating close to a 400 bp standard (Figure 5B,A similar study using T7 phage display as a selection tool
Round 3). In contrast to the cellular selection, the PCRrequired 6–7 rounds of selection to isolate an FKBP12-
product was cloned without gel purification, and 53 ran-containing construct from a human brain cDNA library
dom clones were picked for sequence analysis. Twenty-[19, 28]. As each technology typically requires 2–3 days
one of these clones contained the full-length FKBP12to perform one round of selection, mRNA display pre-
sequence, while an additional 20 sequences encodedsents an expeditious alternative. In addition, the pres-
various fragments of the full-length protein. The re-ence of library-specific sequence tags within the 5-UTR
maining 12 clones contained only UTR sequence, sug-of the mRNA display libraries used in this study should
gesting an incomplete selection, and were not examinedprevent the problems of contamination encountered by
further.phage display approaches.
Representative sequences were chosen to assess theFKBP12 was the only protein identified from our selec-
binding affinities of the corresponding peptides or pro-tion, although multiple isoforms of FK506 binding pro-
teins to FK506 (Figure 6). All proteins were expressedteins are known to exist [29]. This may be because
in vitro using [35S]methionine for radiolabeling, then puri-FKBP12 exhibits the highest affinity for FK506 (Kd  0.4
fied by anti-FLAG M2 immunoprecipitation. The se-nM) [30] compared to other FK506 binding proteins or
lected variants were incubated with a range of immobi-because it is the smallest protein of the FKBP family in
lized FK506 concentrations (10 nM–5 M), and afterthe tissues studied herein [27]. Quantitative PCR analy-
washing, the bound material was quantified by scintilla-sis of the initial cDNA libraries detected products encod-
tion counting. Bound counts were normalized and affini-ing the drug binding domains of FKBP12 and FKBP52
ties were calculated based on a nonlinear regressionbut not FKBP36. However, examination of the cDNA
curve fit. Surprisingly, only proteins that contained the
pools after each round of selection against FK506 re-
full-length FKBP12 sequence bound to FK506. No drug
vealed that FKBP12 was the only immunophilin of the
binding was observed for any of the truncated con-
three that was enriched (data not shown). It is unclear
structs even at the highest FK506 concentration data
whether this bias is indicative of differences in protein point used (5 M).
expression, folding, or drug affinity. Selection using An examination of the FKBP12 framework indicates
mRNA display libraries from normalized cDNA or from the C-terminal amino acids Leu97-Glu107, which form
the cellular mRNA of cell lines or tissues known to have the backbone 	 strand of FKBP12’s 	 sheet, appear
a higher abundance of the larger immunophilins may necessary for structural stability of the protein, and this
promote their enrichment in an affinity selection. Addi- may explain the absence of functional C-terminally trun-
tionally, the versatility of mRNA display should facilitate cated FKBP12 proteins from both selections. Also, the
the application of library size fractionation, larger se- lack of binding to immobilized FK506 observed with an
quence sampling, cDNA array filter analysis, and domi- FKBP12 construct devoid of the first 16 residues (K17-
nant clone depletion to aid in the identification of addi- Q109) (Figure 6) highlights the importance of the N termi-
tional binding proteins in future studies. nus of FKBP12 in forming and/or preserving a FK506
binding fold. Indeed, the selection of FK506 binding
proteins with a Gly1-Val2 truncation supports the obser-
Mapping the Minimal FK506 Binding Domain vation that only minimal deletion of N-terminal sequence
of FKBP12 is tolerated for drug binding. The deficiency of the
mRNA display was applied in the investigation of the shorter FKBP12 fragments in FK506 binding assays sug-
nature of the FK506-FKBP interaction in more detail by gests that the presence of these sequences within the
constructing a cDNA library based on random priming of pool is indicative of either an incomplete selection or
a homogenous mRNA template containing the FKBP12 low-affinity binding of these peptides to FK506 below
the level of assay sensitivity. Overall, this approach maysequence and selection of the minimal protein that medi-
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Figure 5. FKBP12 Domain Library Genera-
tion and Selection against FK506-Biotin
(A) Construction of a random-primed cDNA
library from an FKBP12-containing template.
(i) An FKBP12-containing plasmid was sub-
jected to restriction digest with EarI to give a
1.1 kb segment containing the FKBP12 gene
downstream from the T3 promoter. This tem-
plate was used to synthesize a 661 nucleotide
mRNA with T3 RNA polymerase. Vector, UTR,
and FKBP12 sequences are depicted in
black, gray, and red, respectively. (ii) First-
strand cDNA synthesis was generated by re-
verse transcription of the FKBP12-containing
message with a 9 random nucleotide primer
encoding a C-terminal FLAG epitope and
photoligation site. (iii) After RNase H treat-
ment, random-primed second strand cDNA
synthesis was completed with the Klenow
fragment of E. coli DNA polymerase and an
oligonucleotide containing fixed 5 sequence
(T7 promoter, translation initiation site, li-
brary-specific tag, start codon) in addition to
nine random nucleotides. Unextended primer
was removed by size-exclusion chromatog-
raphy, and the cDNA product was PCR ampli-
fied to give a heterogeneous FKBP12 domain
library that varied in size from 400 bp to
800 bp.
(B) Gel analysis of library cDNA before (Round
0) and after (Round 3) three rounds of in vitro
selection with FK506
provide an alternative to current mapping methods in- tional screens can be used as bait in selections with
libraries constructed from multiple tissue sources. If thevolving proteolytic dissection of a protein of interest
[31]. In this first example using mRNA display to map drug receptor is already known, then mRNA display
technology can potentially be used to map drug bindingthe minimal drug binding domain within a protein, the
resulting map indicates that almost the entire protein to a particular domain within the target protein. More-
over, the identification of additional targets for a givensequence is necessary for functionality. Additional drug
receptor identification and mapping studies using the drug will be extremely helpful in examples of unwanted
side effects or detrimental biodistribution mediatedtechniques described here are currently in progress.
through such targets. The robust conjugation of geno-
type to phenotype coupled with the flexibility of the inConclusions and Future Work
We have demonstrated that mRNA display libraries pro- vitro methodology of mRNA display should allow the
application of automated selection protocols. Parallelvide a potentially valuable tool for probing drug-protein
interactions. Drugs identified in high-throughput func- selections against an array of immobilized small mole-
Figure 6. Schematic Alignment of Select
FKBP12 Constructs Isolated from the
FKBP12 Domain mRNA Display Library after
Three Rounds of Selection with FK506
Each construct was expressed in vitro as a
35S-labeled protein, and its FK506 binding ac-
tivity was assessed in assays where the im-
mobilized drug concentration was varied be-
tween 10 nM and 5 M. Constructs are
identified by their first and last residues. Each
polypeptide sequence contained an initiator
methionine residue followed by the FLAG epi-
tope-containing sequence DYKDDDDKASA.
NB denotes no binding was observed.
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FK506-biotin conjugate. Purified liver, kidney, and bone marrowcules [32, 33] with densities that allow individual features
mRNA display library (250 l, 0.3 pmol) [23] was incubated withto be eluted and amplified by PCR would help to simul-
the control beads (50 l) at RT for 30 min. The beads were captured,taneously identify large numbers of small molecule-
and the supernatant was transferred to a 1.5 ml Eppendorf tube
protein partners. This technology will expedite the iden- containing 50 l of immobilized FK506 magnetic beads. The beads
tification of small molecule-protein interactions and were mixed gently at RT for 30 min, captured, and washed with TBK
buffer (5  200 l). In the last two washes, the beads were allowedadvance our comprehension of disease at the proteomic
to agitate in TBK buffer for 5 min. The cDNA of bound mRNA displaylevel while accelerating the drug discovery process.
constructs was recovered by elution with 0.1 N KOH (2  100 l).
The basic eluates were neutralized with 2 l 1 M Tris-HCl (pH 7)
Significance and 8 l of 1 N HCl, and an aliquot was removed to determine
optimal PCR amplification conditions. Scale-up PCR with mixed
library-specific primers was performed on the remaining eluate us-mRNA display is an emerging proteomic technology
ing the optimized conditions to produce an enriched cDNA library.that allows a protein to be directly linked to its encod-
Subsequent rounds were then repeated as described above.ing nucleic acid. Construction of mRNA display librar-
ies from cDNA allows a comprehensive repertoire of
Cloning and Sequencingcellular proteins to be interrogated for biological inter-
PCR product from the final round of selection was subjected to 2%
actions of medicinal importance. We have expanded agarose gel electrophoresis. A strong band migrating around 400
the scope of mRNA display technology to include natu- bp was excised and purified by spin column (Qiagen). The purified
ral products as targets for in vitro selection. The suc- cDNA was cloned into the TOPO-TA 2.1 vector (Invitrogen), and
individual colonies were picked for direct amplification and se-cessful affinity selection of an mRNA-protein construct
quencing.of FKBP12, the cytosolic receptor of the immunosup-
pressant FK506, demonstrated that in vitro production
Construction of an FKBP12-Derived mRNAof proteins from cellular libraries as nucleic acid-pro-
Display Domain Librarytein fusions allows for proper folding and functionality.
A human FKBP12-containing plasmid was purified from I.M.A.G.EAs more compounds of pharmaceutical interest are
clone ID 591044 and digested with the restriction enzyme EarI. Run-
explored, the potential for mRNA display to discover off transcription of digested plasmid with T3 RNA polymerase gave
novel protein targets of therapeutic or toxicological a 661 nucleotide FKBP12-containing message that was purified by
isopropanol precipitation. This material was used as a templaterelevance will be realized.
for random-primed cDNA synthesis as described previously [23]. A
unique library-specific tag, CTCATAAC, was introduced into the 5-Experimental Procedures
UTR during library construction. Library cDNA was amplified by
PCR, and the corresponding mRNA display library was prepared asSynthesis of FK506-Biotin
described above.To a solution of FK506 (19.7 mg, 24 mol), succinic anhydride (12
mg, 120 mol), and 4-dimethylaminopyridine (DMAP, 5.9 mg, 48
mol) in dichloromethane (DCM, 1 ml), we added triethylamine (TEA, Affinity Selection of a FKBP12-Derived mRNA Display
4l, 30mol), and the solution was stirred for 22 hr at room tempera- Domain Library with FK506-Biotin
ture. The mixture was diluted with dichloromethane (7 ml) and The affinity selection was performed essentially as described for
washed with aqueous 0.1 N HCl, distilled water, and saturated aque- the cellular selection. PCR product after three rounds of selection
ous NaCl. The organic phase was separated, dried over anhydrous was directly cloned into TOPO-TA 2.1 vector, and plasmids were
Na2SO4, filtered, and concentrated. The crude FK506 hemisuccinate purified (Qiagen) and sequenced.
was purified by preparative TLC (100% EtOAc) to give 3 mg (3.3
mol) of a white solid. A mixture of FK506 hemisuccinate (3 mg,
In Vitro Translation of Selected Clones
3.3 mol), N-hydroxysuccinmide (NHS, 0.7 mg, 6 mol), and N,N-
RNA transcripts were produced from PCR templates as described.
dicyclohexylcarbodiimide (DCC, 4.4 mg, 21 mol) in EtOAc (0.5 mL)
Radiolabeled peptides were purified directly from translation reac-
was stirred for 20 hr at room temperature. The reaction mixture was
tions in rabbit reticulocyte lysate (Ambion) by anti-FLAG M2 immu-
centrifuged, and the organic supernatant was evaporated to give
noprecipitation, and their purity was determined by SDS-PAGE/
the crude FK506-hemisuccinic NHS ester, which was used without
autoradiography.
further purification. To a solution of the crude ester in DMF (0.5 ml)
was added a solution of biotin-PEO-LC-NH2 (5.4 mg, 13 mol) in
FK506 Binding Assaysdry dimethylformamide (DMF) (0.3 ml). The mixture was stirred at
Neutravidin agarose (Pierce) was aliquoted into microcentrifuge spinroom temperature for 0.5 hr. The solvent was evaporated, and the
columns (10 50l) and washed with TBK buffer (1 ml). The columnscrude residue was purified by preparative TLC (10% MeOH/dichlo-
were capped and the beads were suspended in 250 l of varyingromethane) to yield 0.8 mg (0.61 mol) of FK506-biotin (3). MS
concentrations of FK506-biotin in TBK buffer (0, 10 nM, 50 nM, 100(MALDI): m/z 1308 (C66H105N5O19S  3H: 1307.63).
nM, 200 nM, 500 nM, 1 M, 2 M, 3 M, and 5 M) and agitated
at RT for 20 min. The beads were washed with TBK buffer (2  0.5Affinity Selection of Cellular mRNA Display Libraries
ml, 1000 rpm, 10 s), and 0.1 pmol of selected [35S]protein in 250with FK506-Biotin
l of TBK buffer was added to each drug matrix. The FK506-beads/Streptavidin-coated magnetic beads (50 l) (SA beads, Dynal) were
protein mixture was gently agitated at RT for 30 min, and unboundwashed twice with TBK buffer (50 mM Tris-HCl [pH 7.0], 150 mM
material was removed by centrifugation (1000 rpm, 10 s). The beadsKCl, 5 mM EDTA, 1 mM DTT, 0.5 mg ml1 BSA, 0.1 mg ml1 salmon
were washed four times with 0.5 ml of TBK buffer. Inverted columnssperm DNA, 0.05% Tween 20) (200 l). The washed beads were
were placed in scintillation vials and centrifuged (4000 rpm, 3 min)suspended in 250 l of TBK buffer, and 8.4 l FK506-biotin (60 M
to maximize recovery of radiolabeled beads, and bound protein wasin 50% MeOH, final conc. 2 M) was added and allowed to agitate
quantified by scintillation counting.gently at RT for 30 min. The beads were washed (2  200 l) and
resuspended in 250 l of TBK buffer. We added 2.5 l biotin (500
mM, final conc. 5 mM), and the beads were agitated at RT for 10 Acknowledgments
min. The FK506 beads were then washed with TBK buffer (2  200
l) and stored in TBK buffer at 4
C until needed. Control beads for The authors would like to thank Rick Baggio, Robert Kuimelis, and
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